36.82
-0.55 (-1.47%)
| Previous Close | 37.37 |
| Open | 36.55 |
| Volume | 508,488 |
| Avg. Volume (3M) | 2,642,152 |
| Market Cap | 5,845,359,104 |
| Price / Earnings (TTM) | 147.28 |
| Price / Earnings (Forward) | 27.55 |
| Price / Sales | 16.31 |
| Price / Book | 25.64 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | 7.11% |
| Operating Margin (TTM) | 27.68% |
| Diluted EPS (TTM) | 0.150 |
| Quarterly Revenue Growth (YOY) | 146.00% |
| Quarterly Earnings Growth (YOY) | -96.60% |
| Total Debt/Equity (MRQ) | 114.40% |
| Current Ratio (MRQ) | 6.25 |
| Operating Cash Flow (TTM) | -40.52 M |
| Levered Free Cash Flow (TTM) | -62.02 M |
| Return on Assets (TTM) | 5.78% |
| Return on Equity (TTM) | 12.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | TG Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 2.00 |
|
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 9.38% |
| % Held by Institutions | 62.69% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| 1832 Asset Management L.P. | 31 Mar 2025 | 1,483,800 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Jun 2025 | Announcement | TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference |
| 02 Jun 2025 | Announcement | TG Therapeutics to Participate in the Jefferies Global Healthcare Conference |
| 05 May 2025 | Announcement | TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance |
| 30 Apr 2025 | Announcement | TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update |
| 08 Apr 2025 | Announcement | TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting |
| 07 Apr 2025 | Announcement | TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |